NCT06469190View on ClinicalTrials.gov

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

June 20, 2025

Study Completion Date

June 20, 2026

Conditions
Nephropathy
Interventions
BIOLOGICAL

anti-CD19 CAR NK cells

"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."

Trial Locations (1)

Unknown

RECRUITING

Shanghai Changhai hospital, Shanghai

All Listed Sponsors
collaborator

Rui Therapeutics Co., Ltd

INDUSTRY

lead

Changhai Hospital

OTHER